Immune checkpoint inhibitors have experienced tremendous uptake in the treatment of bladder cancer following their approval for metastatic disease and, in the case of Keytruda, non-muscle-invasive…
Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs, where available) are the mainstay of biological treatment for moderate to…
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx…
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Chronic Heart Failure disease patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology's coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the hospitalization rate of AHF…